Acadia Projects $0.12 EPS for Q4, Revenues Rise 12.7% to $292.6M
Acadia Pharmaceuticals is forecast to post $0.12 EPS for Q4 2025, a 29.4% decline year-over-year, on $292.6 million in revenues, up 12.7%. The stock carries a Zacks Rank #3 and boasts a +14.92% Earnings ESP after a 3.2% upward EPS estimate revision.
1. Q4 2025 Earnings and Revenue Outlook
Acadia Pharmaceuticals is expected to report $0.12 in EPS for the quarter ended December 2025, reflecting a 29.4% decline from the year-ago period. Revenues are forecast at $292.58 million, marking a 12.7% increase year-over-year, with the consensus EPS estimate having been revised up by 3.2% over the past month.
2. Analyst Signals and Surprise History
The company’s Earnings ESP stands at +14.92%, indicating a strong likelihood of beating consensus estimates when paired with its Zacks Rank #3 (Hold). Over the last four quarters, Acadia has surpassed EPS estimates three times, reinforcing the positive outlook suggested by these metrics.